The proliferative life-span of the stem cells that sustain hematopolesis throughout life is not known. It has been proposed that the sequential loss of telomeric DNA from the ends of human chromosomes with each somatic cell division eventually reaches a critical point that triggers cellular senescence. We now show that candidate human stem cells with a CD34+CD3810 phenotype that were purified from adult bone marrow have shorter telomeres than cells from fetal liver or umbilica cord blood. We also found that cells produced in cytokine-supplemented cultures of purified precursor cells show a proliferation-associated loss of telomeric DNA. These fiings strongly suggest that the proliferative potential of most, if not all, hematopoletic stem cells is limited and decreases with age, a concept that has widespread implications for models of normal and abnormal hematopolesis as well as gene therapy.
CD34+CD3810 phenotype that were purified from adult bone marrow have shorter telomeres than cells from fetal liver or umbilica cord blood. We also found that cells produced in cytokine-supplemented cultures of purified precursor cells show a proliferation-associated loss of telomeric DNA. These fiings strongly suggest that the proliferative potential of most, if not all, hematopoletic stem cells is limited and decreases with age, a concept that has widespread implications for models of normal and abnormal hematopolesis as well as gene therapy.
The requirement for primers and the undirectional 5' -3 3' nature of DNA synthesis by DNA polymerases results in incomplete replication of the terminal 3' strands of linear chromosomes (1) (2) (3) . Eukaryotic chromosomes end in specialized nucleoprotein structures called telomeres (4) and in vertebrates, including humans, telomeres terminate in tandem repeats of (TTAGGG), (5) . Telomeres have been shown to be critical for chromosome stability and function (4) and telomere loss has been shown to signal cell cycle arrest and chromosomal instability in yeast (6, 7) . Telomeric repeats are synthesized by telomerase, a ribonucleoprotein capable of elongating telomeres de novo (8, 9) . In the absence of telomerase, human telomeres shorten with cell divisions and such telomere loss may act as a mitotic clock to eventually signal cell cycle exit and cellular senescence (10, 11) . Loss of telomeric DNA upon proliferation in vitro has been observed in fibroblasts (10, 12) and lymphocytes (13) but not in immortalized tumor cells, which were found to express telomerase activity (9, 14, 15) . Shortening oftelomeres during aging in vivo has been observed with skin dermal and epidermal cells (12, 16) , peripheral blood leukocytes (13, 17) , and colon epithelia (17) but not in sperm DNA (12) .
Most mature cells of the hematopoietic system are relatively short-lived cells that need to be replaced continuously throughout life. A relatively small population of hematopoietic stem cells is ultimately responsible for producing the staggering numbers of cells estimated to represent the daily output of the hematopoietic system (i.e., >1011 cells per day in human adults). Stem cells are usually defined as multipotential cells with self-renewal capacity-i.e., the capacity to give rise to more cells with indistinguishable properties and developmental potential. The maintenance of these properties is believed to be an essential feature of both steady-state hematopoiesis and the regeneration of hematopoiesis from a fraction of the number of stem cells present in the adult as occurs following the administration of myeloblative chemoradiotherapy protocols and injection of a marrow transplant (18) (19) (20) (21) (22) .
Primitive hematopoietic cells in human bone marrow are contained in a very small subpopulation of cells that is characterized by cell surface expression of high levels of CD34 (23) , low levels ofThy-i (24, 25) , and an absence or low levels of CD38 (26) , CD45RA, and CD71 (27) . Recent studies have shown striking ontogeny-related changes in the functional properties of cells with this phenotype (28) . In view of these findings and the age-related loss of telomeric DNA observed in fractionated peripheral blood leukocytes (13) and other somatic cells (12, 16, 17) , we undertook experiments to analyze the length of telomeric DNA in hematopoietic cells in relation to their stage of development.
MATERIALS AND METHODS
Small-Scale Cell Purification. CD34+ CD45RAlo CD7110 cells from fetal liver (13-18 weeks of gestation), umbilical cord blood, and bone marrow (organ donors, 19 and 58 years, respectively) were purified by flow cytometry and cell sorting as described (27, 28) . Purified cells were cultured for up to 4 weeks in serum-free medium supplemented with Steel factor, interleukin 6 (IL-6), granulocyte/macrophage colony-stimulating factor (GM-CSF)/IL-3 fusion protein (PIXY), macrophage CSF, granulocyte CSF, and erythropoietin as described (29) . At various time intervals, the cells in the cultures were harvested, counted, and used for analysis of mean terminal restriction fragment (TRE) length, calculation of population doublings, and continuation of the cultures. Human material used in this study was obtained following protocols approved by local Institutional Review Boards as well as the Ethical Screening Committee of the University of British Columbia.
Large-Scale Cell Purification. Previously frozen bone marrow cells were depleted from cells expressing CD45RA, glycophorin, CD3, CD67, and an unknown platelet antigen (recognized by antibody 3H2 developed in our laboratory) using density separation and high gradient magnetic separation procedures (30 ITo whom reprint requests should be addressed at the f address.
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Telomere Length Analysis. The methods for measurement of mean TRF length have been described elsewhere (12, 13) . In brief, 106 cells at different time points were washed twice in phosphate-buffered saline and the pellet was lysed. Genomic DNA was extracted and 2-5 pg was digested with excess Hinfl and Rsa I (BRL, 10-20 units each), ethanol precipitated, and quantified by fluorometry. One microgram of digested DNA was resolved in 0.5% agarose gels. Gels were dried and subjected to hybridization with 5' end-32P-labeled (C3TA2)3. Gels were washed and then exposed to a Phosphorlmager screen (Molecular Dynamics).
RESULTS
Loss of Telomeric DNA in Hematopoietic Cells in Vivo. Analysis of telomere length in the total nucleated cell population obtained from different bone marrow donors and different fetal liver and cord blood samples demonstrated a loss of telomeric DNA in these tissues at progressive stages ofdevelopment (Fig. 1) . The observed loss oftelomeric DNA from early development (fetal liver or cord blood) to adulthood was highly significant (P < 0.0001, t test). Telomere length also appeared to decrease with the age of the adult bone marrow donors (calculated loss of 9 bp per year), although considerable individual variation in the mean TRF length at any given age was observed. Most likely, these differences reflect inborn differences in TRF length between individuals. This is also suggested by the observed differences in mean TRF length between the various fetal liver and cord blood samples (Fig. 1) (27, 29) . As a result, the calculated loss of telomeric DNA per population "doubling" is not indicative of the possible loss of telomeric DNA per cell division in the most primitive precursors.
Loss of Telomeric DNA in the Most Primitive Hematopoletic Cells. To exclude the possibility that the observed telomere loss in cells from adult bone marrow cultures was restricted to the progeny of a more mature subset of progenitors in the purified cell fraction we examined the mean TRF length ofthe purified cells themselves. This represented a considerable challenge as our current TRF analysis requires DNA from at least 0.5 x 106 cells. To purify sufficient candidate stem cells from CD34+ bone marrow cells in these numbers, lowdensity cells from previously frozen organ donor bone marrow were first depleted from cells expressing lineage antigens using high gradient magnetic separation (30) . CD34+CD3810 cells (26) were then sorted from the magnetically preenriched cells by fluorescence-activated cell sorting.
The mean TRF length of purified CD34+CD3810 cells (>99%o pure) from the bone marrow oftwo different organ donors (aged 16 and 58 years) was compared to that of different cell fractions from the same donors and to that of (control) fetal liver cells (Fig. 4) . As before (Figs. 1-3 ), bone marrow cells had a shorter mean TRF length than fetal liver cells and again an apparent decrease with the age ofthe marrow donor was observed. Small differences in mean telomere length between CD34+CD3810, CD34+CD38hi, and total nucleated bone marrow cells were also found (CD34+CD3810 > CD34+CD38+ > total nucleated bone marrow cells), in agreement with a higher proliferative potential In previous studies, we found that the fraction of cells responding to a mixture of hemopoietic cytokines, the production of CD34+ cells, as well as the proliferation rate of CD34+ cells all decrease during development (28) . This study, showing a decrease in mean telomere length with cell and donor age, suggests that replicative senescence within the hemopoietic lineage may be causally linked to some of these functional differences. Developmental changes in the turnover rate and cytokine responsiveness of primitive human hematopoietic cells (28) are most likely not directly related to changes in the mean telomere length of such cells. However, limitations in the proliferative potential of purified precursors from adult bone marrow could be directly correlated to the observed decrease in mean telomere length. A major obstacle to direct experimental support for this hypothesis is that human telomerase genes have not yet been cloned (33) . However, a large body of evidence on telomere length in somatic cells in vitro and in vivo indicates that telomere length serves as a biomarker of the replicative history of cells (10, 12, 13, 17, 34) .
The findings reported here have several implications for models of both normal and deregulated hematopoiesis. A finite life-span of primitive hematopoietic cells is in agreement with the observed loss of repopulating ability of murine bone marrow in serial transplantation experiments (35) (36) (37) or repeated cycles of cytotoxic treatment (38, 39) . Our findings are also compatible with the higher proliferative potential of fetal versus adult hematopoietic cells observed in various assays (35, 40, 41 
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species cannot be ruled out, another explanation is that in these experiments telomere-related limitations in the proliferative potential of primitive murine precursors were simply not yet reached. A similar situation may exist in various forms of leukemia. At initial stages of the disease, altered signal transduction pathways and/or altered probabilities of differentiation events in a single cell will result in numerical expansion of the leukemic cells. In our current model, this expansion should eventually be limited by critical shortening of telomeric DNA, resulting in signals that trigger cell cycle arrest but also chromosomal instability. Further progression ofthe disease may involve selection of cells that ignore or can bypass the cell cycle arrest signal and, eventually, selection of cells that express the enzyme telomerase (14, 15, 33) . A thorough analysis of telomerase expression in cells from normal hematopoietic tissues at various stages of development as well as cells from patients with various hematological disorders will be required to fully understand the pathophysiology of telomere length dynamics in hematopoietic cells. Further studies are also needed to explore the possibility of extending or maintaining the proliferative potential of adult stem cells by forced expression of exogenous or endogenous telomerase activity. The information derived from such analysis should help to guide the development of novel therapeutic strategies involving transplantation and genetic manipulation of primitive hematopoietic cells for the treatment of a variety of disorders. 
